310 related articles for article (PubMed ID: 12792150)
1. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism.
Schubert M; Bullmann C; Minnemann T; Reiners C; Krone W; Jockenhövel F
Horm Res; 2003; 60(1):21-8. PubMed ID: 12792150
[TBL] [Abstract][Full Text] [Related]
2. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men.
Jockenhövel F; Bullmann C; Schubert M; Vogel E; Reinhardt W; Reinwein D; Müller-Wieland D; Krone W
Metabolism; 1999 May; 48(5):590-6. PubMed ID: 10337859
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.
Behre HM; Kliesch S; Leifke E; Link TM; Nieschlag E
J Clin Endocrinol Metab; 1997 Aug; 82(8):2386-90. PubMed ID: 9253305
[TBL] [Abstract][Full Text] [Related]
4. Effects of various modes of androgen substitution therapy on erythropoiesis.
Jockenhövel F; Vogel E; Reinhardt W; Reinwein D
Eur J Med Res; 1997 Jul; 2(7):293-8. PubMed ID: 9233903
[TBL] [Abstract][Full Text] [Related]
5. Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
Shimon I; Eshed V; Doolman R; Sela BA; Karasik A; Vered I
Osteoporos Int; 2005 Dec; 16(12):1591-6. PubMed ID: 16362147
[TBL] [Abstract][Full Text] [Related]
6. Effects of testosterone replacement therapy on hypogonadal men with osteopenia or osteoporosis: a subanalysis of a prospective randomized controlled study in Japan (EARTH study).
Shigehara K; Konaka H; Koh E; Nakashima K; Iijima M; Nohara T; Izumi K; Kitagawa Y; Kadono Y; Sugimoto K; Iwamoto T; Mizokami A; Namiki M
Aging Male; 2017 Sep; 20(3):139-145. PubMed ID: 28347184
[TBL] [Abstract][Full Text] [Related]
7. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.
Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S
Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.
Ishizaka K; Suzuki M; Kageyama Y; Kihara K; Yoshida K
Asian J Androl; 2002 Jun; 4(2):117-21. PubMed ID: 12085102
[TBL] [Abstract][Full Text] [Related]
9. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.
Katznelson L; Finkelstein JS; Schoenfeld DA; Rosenthal DI; Anderson EJ; Klibanski A
J Clin Endocrinol Metab; 1996 Dec; 81(12):4358-65. PubMed ID: 8954042
[TBL] [Abstract][Full Text] [Related]
10. Current topics in testosterone replacement of hypogonadal men.
Nieschlag E
Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):77-90. PubMed ID: 25617174
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism.
Zacharin MR; Pua J; Kanumakala S
Clin Endocrinol (Oxf); 2003 Jun; 58(6):691-5. PubMed ID: 12780744
[TBL] [Abstract][Full Text] [Related]
12. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
[TBL] [Abstract][Full Text] [Related]
14. [Effect of immunosuppression-induced hypogonadism on bone metabolism after heart transplantation].
Stief J; Sohn HY; Alt A; Uberfuhr P; Theisen K; Stempfle HU
Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1674-8. PubMed ID: 15273918
[TBL] [Abstract][Full Text] [Related]
15. Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients.
Luisi M; Franchi F
J Endocrinol Invest; 1980; 3(3):305-8. PubMed ID: 7000879
[TBL] [Abstract][Full Text] [Related]
16. Effects of long-term testosterone substitutive therapy on bone mineral content in men with hypergonadotrophic hypogonadism.
Medras M; Jankowska EA; Rogucka E
Andrologia; 2001 Jan; 33(1):47-52. PubMed ID: 11167519
[TBL] [Abstract][Full Text] [Related]
17. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
[TBL] [Abstract][Full Text] [Related]
18. Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: A subanalysis of a prospective randomised controlled trial (EARTH study).
Shigehara K; Konaka H; Nohara T; Izumi K; Kitagawa Y; Kadono Y; Iwamoto T; Koh E; Mizokami A; Namiki M
Andrologia; 2018 Feb; 50(1):. PubMed ID: 28497534
[TBL] [Abstract][Full Text] [Related]
19. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
